Deeply oversold in 2016 political uncertainties, the world's largest standalone medical technology company rebounded sharply for the quarter. A leader in biomedical devices, they sold their medical supplies business for $6.1 billion and will pay down debt and repurchase shares.
From Jeff Auxier (Trades, Portfolio)'s second-quarter 2017 shareholder letter.
